Substance Abuse
Nicotine addiction vaccine achieves proof of efficacy
By Cytos Biotechnology
May 16, 2005, 19:07

Cytos Biotechnology AG (SWX:CYTN) announced today that its vaccine candidate CYT002-NicQb to treat nicotine addiction has achieved proof of efficacy.

The phase II clinical trial results were presented by Prof. Dr. Jacques Cornuz (CHUV Lausanne), principal investigator, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, USA, on behalf of the three Swiss study centres. The study included 341 smokers and assessed safety, tolerability and efficacy of the vaccine candidate. Efficacy of the vaccine was determined by continuous abstinence from smoking between week 8 and 24 after treatment start and was measured by self-reporting of the participating smokers and by independent biochemical validation. Two thirds of the smokers received the vaccine, whereas one third received placebo.

All smokers who received the vaccine mounted an anti-nicotine antibody response, which corresponds to an immunological response rate of 100%. Based on the measured levels of antibodies, the vaccinetreated smokers were grouped into a high, a medium, and a low responder group. All smokers who received placebo had no measurable anti-nicotine antibodies in their blood.

The following table provides the continuous abstinence values of the analysis of all smokers from whom complete antibody measurements were available and who refrained from using nicotine replacement products (NRT) (NRT use was considered a major protocol violation): Continuous Abstinence CYT002-NicQb high antibody response 57% (30 / 53)1 medium antibody response 32% (17 / 53)1 40% (64/159) low antibody response 32% (17 / 53)1 Placebo no antibody response 31% (25 / 80)1 1 (Number of continuously abstinent subjects/ total number of subjects in group) The above data show with a high statistical significance (p=0.014) a strong relationship between the induced antibody levels against nicotine (mechanism of action of the vaccine) and the desired clinical effect (continuous abstinence from smoking); and this was irrespective of the unexpected high placebo response observed. The difference of continuous abstinence between the high responder group and the placebo group was highly significant (p=0.004).

Overall cigarette consumption in the high responder group was less than half of that seen in the placebo group (p=0.004). Moreover, the average cigarette consumption by those people who did not achieve continuous abstinence was also lower in the high responder group than in the placebo group (p=0.16). The vaccine was safe and generally well tolerated with common side effects being local injection site reactions and flu-like symptoms, which usually resolved within 24 hours.

Prof. Dr. Jacques Cornuz commented: �I am very excited about the outcome of this study, as the data clearly suggest that antibodies against nicotine are effective in helping people quit smoking. There is certainly no doubt that new approaches such as vaccination are urgently needed. Despite the fact that smoking causes 30% of all cancer deaths, including 87% of deaths from lung cancer, there are 1.3 billion smokers worldwide. And each smoker looses on average more than 10 years of lifetime as a result from this serious addiction.

I believe that the vaccine approach has the potential to dramatically alter the way how we will treat smoking addiction in the future.� Dr. Wolfgang Renner, Chief Executive Officer of Cytos Biotechnology, added: �We are extremely pleased about the results as the data in the high responder group are better than anything we have seen so far. The clear correlation between antibody levels and clinical effect greatly supports us in the further development of this vaccine. It is now our goal to get everybody into this high antibody response range; and to achieve this we have several measures at hand: A) We will increase the dose of the vaccine, as we have already done with other clinical candidates in different indications, B) we can add more injections as even after the fourth injection there appeared to be no antibody plateau, and C) we will certainly use these findings in our ongoing formulation development. But most importantly, the data show elegantly that we can use the body�s own defence, the immune system, to modulate even such complex conditions like addiction. This finding is extremely important with respect to our pipeline of 27 vaccine candidates in other major disease areas like high blood pressure, obesity or Alzheimer�s disease where we use the same basic ImmunodrugTM principle.� More information about the phase II study, the vaccine candidate CYT002-NicQb and general information about smoking and nicotine addiction can be found on www.smokersvaccine.com.

All rights reserved by www.rxpgnews.com